CompletedPhase 4

Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation

United States15 participantsStarted 2020-12-23

Plain-language summary

The purpose of this study is to compare the efficacy of subcutaneous versus oral mu-opioid receptor antagonist therapy in opioid induced constipation that is refractory to other bowel regimens.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Complaint of opioid-induced constipation refractory to other therapy (enemas, laxatives, stool softeners) * Age≥18y/o * Not pregnant or lactating (negative urinary pregnancy test) * No contraindication to Methylnaltrexone or Naloxegol Exclusion Criteria: * Age\<18y/o * Pregnancy or lactation * Contraindication to Methylnaltrexone or Naloxegol * Assigned NPO * Small bowel obstruction

What they're measuring

Occurrence of Bowl Movement

Timeframe: 24 hours

Trial details

NCT IDNCT03523520

SponsorUniversity of Missouri-Columbia

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-03-31

Results submitted2024-07-02

View on ClinicalTrials.gov More Constipation Drug Induced trials